Funding for this research was provided by:
same as corresponding author
Norges Forskningsråd (GlobVac no 234493)
Ministry of Health | Statens Serum Institut
Received: 18 March 2021
Accepted: 25 October 2021
First Online: 22 November 2021
: The authors have no competing interests or other interests that might be perceived to influence the results and/or discussion reported in this paper. M.R., M.K., P.B., and R.M. are employees at SSI that develop the H56:IC31 vaccine. They are not inventors of patents and have no financial interests.